{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T22:40:01Z","timestamp":1754174401611,"version":"3.41.2"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Atherosclerosis remains a leading cause of morbidity and mortality, with revascularization remaining a cornerstone of management. Conventional revascularization modalities remain challenged by target vessel reocclusion\u2014an event driven by mechanical, thrombotic, and proliferative processes. Despite considerable advancements, restenosis remains the focus of ongoing research. Adjunctive agents, including dipyridamole, offer a multitude of effects that may improve vascular homeostasis. We sought to quantify the potential therapeutic impact of dipyridamole on vascular occlusion. We performed a literature search (EMBASE and MEDLINE) examining studies that encompassed 3 areas: (1) one of the designated medical therapies applied in (2) the setting of a vascular intervention with (3) an outcome including vascular occlusion rates and\/or quantification of neointimal proliferation\/restenosis. The primary outcome was vascular occlusion rates. The secondary outcome was the degree of restenosis by neointimal quantification. Both human and animal studies were included in this translational analysis. There were 6,839 articles screened, from which 73 studies were included, encompassing 16,146 vessels followed up for a mean of 327.3 days (range 7\u20133650 days). Preclinical studies demonstrate that dipyridamole results in reduced vascular occlusion rates {24.9% vs. 48.8%, risk ratio 0.53 [95% confidence interval (CI) 0.40\u20130.70], I<jats:sup>2<\/jats:sup> = 39%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.00001}, owing to diminished neointimal proliferation [standardized mean differences \u22121.13 (95% CI \u22121.74 to \u22120.53), I<jats:sup>2<\/jats:sup> = 91%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0002]. Clinical studies similarly demonstrated reduced occlusion rates with dipyridamole therapy [23.5% vs. 31.0%, risk ratio 0.77 (95% CI 0.67\u20130.88), I<jats:sup>2<\/jats:sup> = 84%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001]. Dipyridamole may improve post-intervention vascular patency and mitigate restenosis. Dedicated studies are warranted to delineate its role as an adjunctive agent after revascularization.<\/jats:p>","DOI":"10.1097\/fjc.0000000000000976","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T17:02:54Z","timestamp":1616605374000},"page":"450-457","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Revisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis"],"prefix":"10.1097","volume":"77","author":[{"given":"Trevor","family":"Simard","sequence":"first","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"},{"name":"Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pouya","family":"Motazedian","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"},{"name":"Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Dhaliwal","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Di Santo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"},{"name":"Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Daniel","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"},{"name":"H\u00f4pital Cardiologique du Haut-L\u00e9v\u00eaque, CHU Bordeaux, Bordeaux-Pessac, France;"},{"name":"L'Institut de Rythmologie et Mod\u00e9lisation Cardiaque (LIRYC), Universit\u00e9 de Bordeaux, Bordeaux-Pessac, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisha","family":"Labinaz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer","family":"Short","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Parlow","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Joseph","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adil","family":"Rasheed","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Rockley","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery, the Ottawa Hospital, Ottawa, Ontario, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Marbach","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Cecile","family":"Domecq","sequence":"additional","affiliation":[{"name":"Health Sciences Library, The University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Russo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aun-Yeong","family":"Chong","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob S.","family":"Beanlands","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"},{"name":"Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hibbert","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;"},{"name":"Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,4]]},"reference":[{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJM199912233412601","article-title":"Coronary angioplasty with or without stent implantation for acute myocardial infarction","volume":"341","author":"Grines","year":"1999","journal-title":"New Engl J Med."},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa067193","article-title":"Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents","volume":"356","author":"Stone","year":"2007","journal-title":"New Engl J Med."},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","article-title":"Drug-eluting or bare-metal stents for coronary artery disease","volume":"375","author":"Bonaa","year":"2016","journal-title":"N Engl J Med."},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41569-019-0249-3","article-title":"Saphenous vein grafts in contemporary coronary artery bypass graft surgery","volume":"17","author":"Caliskan","year":"2019","journal-title":"Nat Rev Cardiol."},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/CIRCRESAHA.116.303504","article-title":"Surgical intervention for peripheral arterial disease","volume":"116","author":"Vartanian","year":"2015","journal-title":"Circ Res."},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s42155-019-0072-2","article-title":"Prolonged versus brief balloon inflation during arterial angioplasty for de novo atherosclerotic disease: a systematic review and meta-analysis","volume":"2","author":"Rockley","year":"2019","journal-title":"CVIR Endovascular"},{"key":"R9-20250802","first-page":"35","article-title":"The evolution of coronary stents: a brief review","volume":"30","author":"Simard","year":"2014","journal-title":"Can J Cardiol."},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/187152911795945169","article-title":"Pathogenesis of neointima formation following vascular injury","volume":"11","author":"Pourdjabbar","year":"2011","journal-title":"Cardiovasc Hematol Disord Drug Targets."},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/cvr\/cvp156","article-title":"Inhibition of endothelial progenitor cell glycogen synthase kinase-3beta results in attenuated neointima formation and enhanced re-endothelialization after arterial injury","volume":"83","author":"Hibbert","year":"2009","journal-title":"Cardiovasc Res."},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2018.02.135","article-title":"Role of plasminogen activator inhibitor-1 in coronary pathophysiology","volume":"164","author":"Jung","year":"2018","journal-title":"Thromb Res."},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1096\/fj.13-230417","article-title":"Heat shock protein 27 attenuates neointima formation and accelerates reendothelialization after arterial injury and stent implantation: importance of vascular endothelial growth factor up-regulation","volume":"28","author":"Ma","year":"2014","journal-title":"Faseb J"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1871529X18666181011103719","article-title":"Adenosine as a marker and mediator of cardiovascular homeostasis: a translational perspective","volume":"19","author":"Simard","year":"2018","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"R15-20250802","first-page":"14","article-title":"Progenitor cells for arterial repair: incremental advancements towards therapeutic reality","volume":"2017","author":"Simard","year":"2017","journal-title":"Stem Cell Int."},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"s39","DOI":"10.1161\/ATVBAHA.107.160226","article-title":"Translational therapeutics of dipyridamole","volume":"28","author":"Kim","year":"2008","journal-title":"Arteriosclerosis, Thromb Vasc Biol."},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00005344-200009000-00011","article-title":"Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication","volume":"36","author":"Liu","year":"2000","journal-title":"J Cardiovasc Pharmacol."},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.104.530097","article-title":"Coronary stent restenosis in patients treated with cilostazol","volume":"112","author":"Douglas","year":"2005","journal-title":"Circulation"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0950-821X(05)80509-2","article-title":"Forskolin impregnation of small calibre PTFE grafts lowers early platelet graft sequestration and improves patency in a sheep model","volume":"5","author":"Christenson","year":"1991","journal-title":"Eur J Vasc Surg."},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0735-1097(00)00679-3","article-title":"8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo","volume":"36","author":"Indolfi","year":"2000","journal-title":"J Am Coll Cardiol."},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-018-0166-4","article-title":"Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"Jung","year":"2018","journal-title":"Thromb J."},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijcard.2011.12.035","article-title":"Percutaneous coronary intervention with or without on-site coronary artery bypass surgery: a systematic review and meta-analysis","volume":"167","author":"Simard","year":"2013","journal-title":"Int J Cardiol."},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res."},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol."},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jtcvs.2003.11.015","article-title":"Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts","volume":"128","author":"Fujinaga","year":"2004","journal-title":"J Thorac Cardiovasc Surg."},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0149-2918(97)80058-6","article-title":"A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation","volume":"19","author":"Kunishima","year":"1997","journal-title":"Clin Ther."},{"key":"R28-20250802","first-page":"322","article-title":"Locally applied cilostazol suppresses neointimal hyperplasia and medial thickening in a vein graft model","volume":"13","author":"Yamamoto","year":"2007","journal-title":"Ann Thorac Cardiovasc Surg."},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1708538114533962","article-title":"Inhibitory effect of adenosine on intimal hyperplasia and proliferation of smooth muscle cells in a carotid arterial anastomosis animal model","volume":"23","author":"Albayrak","year":"2015","journal-title":"Vascular"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/HYPERTENSIONAHA.115.05912","article-title":"Adenosine attenuates human coronary artery smooth muscle cell proliferation by inhibiting multiple signaling pathways that converge on cyclin D","volume":"66","author":"Dubey","year":"2015","journal-title":"Hypertension"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1161\/ATVBAHA.112.252924","article-title":"Adenosine A 2B receptor agonism inhibits neointimal lesion development after arterial injury in apolipoprotein E\u2013deficient mice","volume":"32","author":"Bot","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/icvts\/ivu087","article-title":"Effect of the P2Y12 antagonist ticagrelor on neointimal hyperplasia in a rabbit carotid anastomosis model\u2020","volume":"19","author":"S\u00fcrer","year":"2014","journal-title":"Interactive Cardiovasc Thorac Surg."},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/heartjnl-2015-308691","article-title":"Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery","volume":"102","author":"Saw","year":"2016","journal-title":"Heart"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.2018.3197","article-title":"Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial","volume":"319","author":"Zhao","year":"2018","journal-title":"JAMA"},{"key":"R35-20250802","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jacc.2019.11.058","article-title":"Stent-related adverse events >1 year after percutaneous coronary intervention","volume":"75","author":"Madhavan","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2015.10.044","article-title":"Exercise-based cardiac rehabilitation for coronary heart disease","volume":"67","author":"Anderson","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"R37-20250802","doi-asserted-by":"crossref","first-page":"E345","DOI":"10.1503\/cmaj.180125","article-title":"Tackling smoking cessation systematically among inpatients with heart disease","volume":"190","author":"Reid","year":"2018","journal-title":"Can Med Assoc J."},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"New Engl J Med."},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"New Engl J Med."},{"key":"R40-20250802","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"R41-20250802","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New Engl J Med."},{"key":"R42-20250802","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.clinthera.2014.06.010","article-title":"The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication","volume":"36","author":"Hong","year":"2014","journal-title":"Clin Ther."},{"key":"R43-20250802","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/clpt.1989.12","article-title":"Oral dipyridamole increases plasma adenosine levels in human beings","volume":"45","author":"German","year":"1989","journal-title":"Clin Pharmacol Ther."},{"key":"R44-20250802","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0167-5273(96)02712-X","article-title":"Pharmacological preconditioning of ischemic heart disease by low-dose dipyridamole","volume":"56","author":"Pasini","year":"1996","journal-title":"Int J Cardiol."},{"key":"R45-20250802","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10557-005-6896-0","article-title":"Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation","volume":"19","author":"Li","year":"2005","journal-title":"Cardiovasc Drugs Ther."},{"key":"R46-20250802","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/01.HYP.31.1.516","article-title":"Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors","volume":"31","author":"Dubey","year":"1998","journal-title":"Hypertension"},{"key":"R47-20250802","first-page":"CD001820","article-title":"Dipyridamole for preventing stroke and other vascular events in patients with vascular disease","volume":"1","author":"De Schryver","year":"2007","journal-title":"Cochrane Database Syst Rev."},{"key":"R48-20250802","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/01.CIR.82.3.765","article-title":"Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole","volume":"82","author":"Sanz","year":"1990","journal-title":"Circulation"},{"key":"R49-20250802","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa0805840","article-title":"Effect of dipyridamole plus aspirin on hemodialysis graft patency","volume":"360","author":"Dixon","year":"2009","journal-title":"New Engl J Med."},{"key":"R50-20250802","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0741-5214(91)90022-M","article-title":"Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial","volume":"13","author":"McCollum","year":"1991","journal-title":"J Vasc Surg."},{"key":"R51-20250802","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/0735-1097(94)90096-5","article-title":"Effects of low dose aspirin (50 mg\/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1 year","volume":"24","author":"Van Der Meer","year":"1994","journal-title":"J Am Coll Cardiol."},{"key":"R52-20250802","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJM198806303182603","article-title":"Aspirin and dipyridamole in the prevention of Re-stenosis after percutaneous transluminal coronary angioplasty","volume":"318","author":"Schwartz","year":"1988","journal-title":"New Engl J Med."},{"key":"R53-20250802","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jcin.2018.04.022","article-title":"Effects of ticagrelor, prasugrel, or clopidogrel on endothelial function and other vascular biomarkers: a randomized crossover study","volume":"11","author":"Ariotti","year":"2018","journal-title":"JACC Cardiovasc Interv."},{"key":"R54-20250802","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","article-title":"Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome","volume":"63","author":"Bonello","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"R55-20250802","doi-asserted-by":"crossref","first-page":"e012228","DOI":"10.1161\/JAHA.119.012228","article-title":"Evaluation of plasma adenosine as a marker of cardiovascular risk: analytical and biological considerations","volume":"8","author":"Simard","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"R56-20250802","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1074248411410883","article-title":"Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model","volume":"17","author":"Van Giezen","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"R57-20250802","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(17)32849-0","article-title":"Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial","volume":"391","author":"Bath","year":"2018","journal-title":"The Lancet"},{"key":"R58-20250802","first-page":"E47","article-title":"Aggrenox significantly reduces restenosis and plaque burden in cerebrovascular arterial stents","volume":"42","author":"English","year":"2011","journal-title":"Stroke"},{"key":"R59-20250802","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med."},{"key":"R60-20250802","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clinthera.2018.11.014","article-title":"Colchicine in cardiovascular disease: repurposing an ancient gout drug","volume":"41","author":"Thompson","year":"2019","journal-title":"Clin Ther."}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000000976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T22:00:19Z","timestamp":1754172019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000000976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000000976","relation":{},"ISSN":["0160-2446"],"issn-type":[{"type":"print","value":"0160-2446"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"2020-07-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}